BEYONDSPRING INC.

BYSI
Delayed Quote. Delayed  - 07/10 04:00:00 pm
15.26USD -3.60%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.

Number of employees : 61 people.
Managers
Name Title
Lan Huang Chairman & Chief Executive Officer
Richard J. Daly Chief Operating Officer
Dong Heng Liu Chief Financial Officer
Ramon W. Mohanlal Director & Chief Medical Officer
James Tonra Chief Scientific Officer
Matthew Kirkby Independent Director
Quan Qi Song Independent Director
Yanbin Xie Director
Christine Ying Zhao Independent Director
Patrick Fabbio Independent Director
Shareholders
Name Equities %
Lan Huang 10,367,037 37.2%
Decheng Capital LLC 2,688,912 9.64%
Mulong Liu 2,105,494 7.55%
Quan Qi Song 689,759 2.47%
Shanghai Fosun Industry Investment Co. Ltd. 311,128 1.12%
HBM Partners AG (Investment Management) 285,130 1.02%
Ramon W. Mohanlal 220,098 0.79%
SSgA Funds Management, Inc. 206,339 0.74%
BlackRock Fund Advisors 162,337 0.58%
Northern Trust Investments, Inc.(Investment Management) 158,383 0.57%
Company contact information
BeyondSpring, Inc.
28 Liberty Street
39th floor
New York, NY 10005

Phone : +1.646.305.6387
Fax : +1.646.882.4228
Web : http://www.beyondspringpharma.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
BEYONDSPRING INC.-1.55%459
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955
BIONTECH SE107.67%15 956
BEIGENE, LTD.18.26%15 307
SAREPTA THERAPEUTICS, INC.30.82%13 165
HUALAN BIOLOGICAL ENGINEERING INC.79.89%12 676
ARGENX SE55.29%12 129
NEUROCRINE BIOSCIENCES, INC.20.65%12 044
EXELIXIS, INC.37.23%7 648
ASCENDIS PHARMA A/S-1.55%7 151
BIOCON LIMITED41.06%6 533
ZAI LAB LIMITED109.11%6 495
ACCELERON PHARMA INC.88.59%5 941
PEPTIDREAM INC.-17.14%5 465
ULTRAGENYX PHARMACEUTICAL INC.101.97%5 154
REATA PHARMACEUTICALS, INC.-24.47%5 132
MIRATI THERAPEUTICS, INC.-10.81%5 016